Introduction
============

Lung cancer has been the most common cancer in both incidence and mortality worldwide \[[@b1-crt-2016-178]\]. However, a decrease in lung cancer incidence and mortality has been observed in men in many developed countries, whereas an increase or no significant changes have been observed in women. When the histological types of lung cancer are considered, the incidence of squamous cell carcinoma and small cell carcinomas has been decreasing, whereas the incidence of adenocarcinomas has been increasing in both men and women \[[@b2-crt-2016-178]-[@b5-crt-2016-178]\]. This may be explained by changes in the prevalence of tobacco smoking, which is the most important risk factor for lung cancer and accounts for 70%-90% of the lung cancer burden \[[@b6-crt-2016-178],[@b7-crt-2016-178]\]. The strongest association between smoking and lung cancer is observed for squamous cell carcinoma and small cell carcinomas (odds ratio, 63 to 111 for smokers \> 30 cigarettes/day), but this association is still quite high for adenocarcinomas (odds ratio, 19 to 21 for smokers \> 30 cigarettes/day) \[[@b8-crt-2016-178]\].

In Korea, the lung cancer mortality in both sexes as well as the incidence in men have decreased, whereas the incidence in women has increased over the last few decades \[[@b9-crt-2016-178]\]. In addition, early detection by screening and the introduction of new chemotherapy and molecular targeted-agents may improve the survival of lung cancer patients. The objectives of the current study were to examine the trends in the lung cancer incidence, mortality, and survival in Korea. For the incidence and survival, the trends for each histological type were also assessed.

Materials and Methods
=====================

1. Lung cancer incidence
------------------------

The Korea Central Cancer Registry (KCCR), a nation-wide, hospital-based cancer registry, was initiated by the Ministry of Health and Welfare, Korea in 1980. Since 1999, the KCCR expanded the cancer registration to cover the entire Korean population under the Population-Based Regional Cancer Registry program. The age- (5-year intervals) and sex-specific incidence rates and the number of cases for lung cancer patients between 1999 and 2012 were obtained from the Korea National Cancer Incidence Database. The histological subtypes of lung cancer were classified as follows: carcinomas (International Classification of Diseases for Oncology third edition morphological codes 8010-8576), sarcoma (8800-8811, 8830, 8840-8921, 8990-8991, 9040, 9044, 9120-9133, 9150, and 9540-9581), other specified cancers, including pulmonary blastoma, and unspecified (8000-8005). Carcinomas were further classified as follows: squamous cell carcinoma (8050-8078 and 8083-8084), adenocarcinoma (8140, 8211, 8230-8231, 8250-8260, 8323, 8480-8490, 8550-8551, 8570-8574, and 8576), small-cell carcinoma (8041-8045 and 8246), large-cell carcinoma (8010-8012, 8014-8031, 8035, and 8310), and other specified carcinomas.

The age-standardized rates (ASRs) were calculated using the mid-year population of 2000 as the standard population. The annual percent changes (APC) for the incidence rates were calculated based on a linear model using the following formula: (exp(*b*)−1)×100, where *b* is the slope of the regression of the natural logarithm of the ASR in a calendar year \[[@b10-crt-2016-178]\]. The 95% confidence intervals were obtained with a standard error from the fit of the regression and the t-distribution function \[[@b11-crt-2016-178]\]. All analyses were stratified according to sex.

2. Lung cancer mortality
------------------------

The lung cancer mortality data were obtained from the Statistics Korea for the years 1983-2013 (<http://kosis.kr/>). The ASRs for mortality, as well as the truncated rates for the four age groups (0-39, 40-59, 60-69, and ≥ 70 years) were estimated using the mid-year population of 2000 as the standard population. The trends in lung cancer mortality were tested using Joinpoint regression models, using Joinpoint software ver. 3.5.3 \[[@b12-crt-2016-178]\]. A maximum of four Joinpoints were allowed, and the default settings were used.

To evaluate the birth cohort effects on lung cancer mortality, 5-year age groups starting at age 20 years were categorized. The age-specific mortality rates were illustrated by the birth cohort. To evaluate the birth-cohort effects after adjusting for age and period effects, a log-linear model using the intrinsic estimator method was performed on the assumption that the number of deaths in each age group followed a Poisson distribution \[[@b13-crt-2016-178]\].

3. Lung cancer survival
-----------------------

The survival duration for registered lung cancer patients was determined as the interval between the date of the initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. The 5-year relative survival rates were calculated using the Ederer II method \[[@b14-crt-2016-178]\] based on an algorithm written in SAS by Dickman \[[@b15-crt-2016-178]\] with minor modifications. The 5-year relative survival rates of 1993-1997 and 2008-2012 were compared by the percentage changes. In addition, the excess risk model with a Poisson error structure was used to determine the difference in survival between 1993-1997 and 2008-2012 \[[@b16-crt-2016-178]\]. Statistical analysis was performed using Stata/SE 12.0 for Windows (StataCorp LP, College Station, TX) and SAS ver. 9.3 software (SAS Institute Inc., Cary, NC).

Results
=======

1. Lung cancer incidence
------------------------

In men, despite the increase in the crude incidence rates for lung cancer from 41.1/100,000 in 1999 to 60.9/100,000 in 2012 with an APC of 3.4%, the age-standardized incidence rate decreased from 51.8/100,000 in 1999 to 44.9/100,000 in 2012 with an APC of −0.9% ([Table 1](#t1-crt-2016-178){ref-type="table"}). The most frequent histological type was squamous cell carcinoma until 2010; however, since 2011, adenocarcinoma has been the most commonly diagnosed cancer. The number of new lung cancer cases increased from 9,722 in 1999 to 15,350 in 2012 ([Table 1](#t1-crt-2016-178){ref-type="table"}). The proportion of adenocarcinomas also increased during the same period (17.8% in 1999 and 32.9% in 2012), whereas the proportion of squamous cell carcinomas decreased (34.9% in 1999 and 30.8% in 2012) ([Fig. 1](#f1-crt-2016-178){ref-type="fig"}). A significant decrease in ASRs for the incidence was observed for squamous cell carcinomas, small cell carcinomas, and large cell carcinomas, whereas the ASR for the adenocarcinoma incidence increased significantly (APC, 4.1%) between 1999 and 2012 ([Table 1](#t1-crt-2016-178){ref-type="table"}, [Fig. 2A](#f2-crt-2016-178){ref-type="fig"}).

In women, both the crude rates and ASRs for the lung cancer incidence increased between 1999 and 2012 with an APC of 5.2% and 1.7% for the crude rate and incidence, respectively ([Table 1](#t1-crt-2016-178){ref-type="table"}). Adenocarcinoma was the most frequent histological subtype during this period. The proportion of adenocarcinomas increased from 34.5% in 1999 to 61.7% in 2012 ([Fig. 1](#f1-crt-2016-178){ref-type="fig"}). Similar to men, both the crude rate and the ASR for adenocarcinoma incidence increased between 1999 and 2012, with an APC of 10% for the crude rate and 6.6% for ASR, whereas the ASRs for the incidence of squamous cell carcinomas, small cell carcinomas, and large cell carcinomas decreased ([Table 1](#t1-crt-2016-178){ref-type="table"}, [Fig. 2B](#f2-crt-2016-178){ref-type="fig"}).

2. Lung cancer mortality
------------------------

In both men and women, the number of deaths from lung cancer increased between 1983 and 2013 ([S1 Table](#SD1-crt-2016-178){ref-type="supplementary-material"}). In 2013, a total of 12,512 men and 4,653 women died from lung cancer, which places lung cancer as the most common cancer site for death in both sexes \[[@b9-crt-2016-178]\]. The lung cancer mortality rapidly increased between 1983 and 1994, with an APC of 9.4% for men and 7.6% for women ([Table 2](#t2-crt-2016-178){ref-type="table"}). From 1994, the slope of the increase began to stabilize, and since 2002, it started to decrease ([Table 2](#t2-crt-2016-178){ref-type="table"}). In stratified analysis according to age groups, there was a decline in mortality for the younger age groups in both men and women. For men, there was a significant decline in mortality from 1992 for the 40-59-year age group, from 2001 for the 60-69-year age group, and from 2002 for the ≥ 70 year age group. Similarly, for women, there was a decline in mortality from 1983 for the 0-39-year age group, from 1993 for the 40-59-year age group, from 1994 for the 60-69-year age group, and from 2002 for the ≥ 70 year age group.

Among elderly individuals aged ≥ 65 years, the ASR for the lung cancer mortality was highest among those born in the 1920s. When adjusting for age and period effects, the risk ratio for the lung cancer mortality was highest among those born between 1924 and 1929. After that, the younger generation had a lower risk of lung cancer mortality ([Fig. 3A](#f3-crt-2016-178){ref-type="fig"} and [B](#f3-crt-2016-178){ref-type="fig"}).

3. Lung cancer survival
-----------------------

Overall, the 5-year relative survival of lung cancer has improved significantly from 11.2% among patients diagnosed between 1993 and 1997 to 19.3% among patients diagnosed between 2008 and 2012 for men, and from 14.7% to 28.2%, respectively, in women ([Table 3](#t3-crt-2016-178){ref-type="table"}). An improved survival rate was observed for almost all histology groups, except for other specified carcinomas or other specified cancers. According to the histological types, adenocarcinomas showed the highest improvement for survival between 1993-1997 and 2008-2012, and an 8.6% improvement in the 5-year survival rate was observed for squamous cell carcinoma between 1993-1997 and 2008-2012. Otherwise, there has been little change in the 5-year survival rate of large cell carcinoma and sarcoma. Adenocarcinomas showed the highest 5-year survival rate in both men and women (27.1% for men and 38.3% in women) among patients diagnosed between 2008 and 2012.

Discussion
==========

Despite the increase in the number of lung cancer patients, the ASR for the lung cancer incidence decreased between 1999 and 2012 in men in Korea, whereas it increased in women during this same time. Until 2010, squamous cell carcinoma was the most frequently diagnosed histological type in men, then adenocarcinoma was the most frequent histologic type. In women, adenocarcinoma has been the most frequent histological type since 1999.

The cigarette smoking rate has declined from 72% in 1992 to 42% in 2013 in adult men \[[@b17-crt-2016-178],[@b18-crt-2016-178]\], whereas the smoking rates in adult women did not show significant changes, remaining at approximately 5%-8% \[[@b17-crt-2016-178]\]. It has been suggested that the reduction in tobacco consumption since the 1960s has been followed by a decrease in squamous cell carcinoma incidence, but not adenocarcinoma incidence in French men \[[@b19-crt-2016-178]\]. Moreover, the increase in adenocarcinoma incidence may be due to the detection of asymptomatic cases or improved diagnostic techniques \[[@b19-crt-2016-178]\]. On the other hand, an increase in adenocarcinoma may also be explained by the changes in cigarette manufacturing, including the introduction of filtered, lower tar- and lower nicotine-containing cigarettes \[[@b20-crt-2016-178]\]. Furthermore, nicotine-addicted smokers tend to inhale low-yield filtered cigarettes deeper and more intensively than non-filtered higher-yield cigarettes to satisfy their nicotine needs; this leads to a more peripheral distribution of tobacco smoke in the lung and promotes peripheral tumors, such as adenocarcinomas \[[@b20-crt-2016-178],[@b21-crt-2016-178]\].

A decrease in mortality in male lung cancer has been observed in many developed countries \[[@b4-crt-2016-178],[@b22-crt-2016-178],[@b23-crt-2016-178]\]. Lung cancer mortality is strongly influenced by tobacco consumption, peaking 20-30 years after the peak in tobacco consumption \[[@b23-crt-2016-178],[@b24-crt-2016-178]\]. Price and non-price tobacco control policies were introduced as early as 1986; these policies restricted advertising and included health warnings on cigarette packages in Korea \[[@b18-crt-2016-178]\]. In addition, in 1995, the Korean government passed the National Health Promotion Act and strengthened tobacco control policies \[[@b18-crt-2016-178]\]. The consequent decrease in lung cancer mortality since 2002 in Korea is consistent with previous reports \[[@b25-crt-2016-178]\].

The improvement in the lung cancer survival rate may be related to several factors, including the introduction of the target agents \[[@b26-crt-2016-178]\], earlier diagnosis \[[@b27-crt-2016-178]\], and a decrease in surgical mortality \[[@b27-crt-2016-178]\]. The introduction of (neo)adjuvant chemotherapy contributed to the improvement of stages I-III resectable non-small cell lung cancer patients \[[@b28-crt-2016-178]\]. Currently, adjuvant chemotherapy is applied to patients with resected stage II or III non-small cell lung cancer, and in patients with stage IB with a resected lesion of 4 cm or larger \[[@b29-crt-2016-178]\]. These findings appear to contribute to improved survival in adenocarcinoma. In addition, patients are now more likely to have access to health insurance and receive a timely diagnosis as well as high quality treatment and supportive care.

The limitations of the current study include a relatively high proportion of unspecified histology. The proportion of unspecified cancer was 31.6% in 1999, which improved to 14.2% in 2012. This can be explained in part by the improvements in diagnostic methods and in the quality of characterization, which may lead to more specific diagnoses. On the other hand, the substantial increase in adenocarcinoma cases cannot be explained by a misclassification of other histologic types to unspecified cancers. Another limitation regarding survival analysis was due to the limited information in stage information. Among the 88,655 lung cancer patients diagnosed between 2008 and 2012, the Surveillance, Epidemiology, and End Results stage information for 9,753 patients (11.0%) was missing \[[@b30-crt-2016-178]\]. The 5-year relative survival was 53.9% for localized cancer, 29.9% for regional cancer, 5.1% for distant cancer, and 15.8% for unknown stage cancers. Therefore, we cannot rule out the possibility that improved stage information might contribute to improvements in overall survival.

Despite these limitations, the KCCR provides reasonably high quality data ([S2 Table](#SD2-crt-2016-178){ref-type="supplementary-material"}). For instance, for lung cancer, the proportion of cases with a death certificate only was 10.8% in 1999 and improved to 3.3% in 2012. Moreover, the mortality/ incidence ratio and the proportion of microscopic verification were in the acceptable ranges.

Conclusion
==========

The lung cancer mortality began to decrease in both men and women in 2002. Since 1999, the of incidence lung cancer has decreased among men, whereas it has increased among women. Adenocarcinomas have become the most frequent histological type in both men and women. Finally, there has been an improvement in the 5-year relative survival of lung cancer patients.
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###### 

CR and ASR per 100,000a) for lung cancer and APC by sex and histological subtypes, the Korea Central Cancer Registry, 1999-2012

  Histological group                                                     Rate    Year    APC     95% CI   p-value                                                                                                                       
  ---------------------------------------------------------------------- ------- ------- ------- -------- --------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------------- --------- --
  **Men**                                                                                                                                                                                                                               
   Overall                                                               Cases   9,722   9,788   10,473   10,956    11,187   11,961   12,497   12,682   13,182   13,593   14,240   14,914   15,319   15,350                             
  CR                                                                     41.1    41.0    43.6    45.4     46.2      49.2     51.2     51.7     53.5     54.9     57.2     59.7     61.1     60.9     3.4      3.1 to 3.6      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     51.8    50.3    51.5    51.6     50.4      51.3     51.6     49.9     49.4     48.3     48.2     48.1     47.2     44.9     −0.9     −1.2 to −0.6    \< 0.01   
   Carcinoma                                                             Cases   6,967   6,947   7,916    8,262     8,735    9,373    9,861    10,361   10,907   11,354   12,148   12,741   13,173   13,365                             
  CR                                                                     29.4    29.1    32.9    34.2     36.0      38.5     40.4     42.3     44.3     45.9     48.8     51.0     52.5     53.1     5.0      4.6 to 5.4      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     36.0    34.6    37.8    37.8     38.3      39.2     39.6     39.9     40.0     39.6     40.5     40.6     40.2     38.8     0.9      0.5 to 1.3      \< 0.01   
   Squamous cell carcinoma                                               Cases   3,394   3,256   3,572    3,746     3,724    4,000    4,034    4,172    4,312    4,097    4,575    4,627    4,707    4,737                              
  CR                                                                     14.3    13.6    14.9    15.5     15.4      16.4     16.5     17.0     17.5     16.5     18.4     18.5     18.8     18.8     2.4      2.0 to 2.9      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     17.7    16.3    17.2    17.3     16.4      16.9     16.4     16.2     16.0     14.3     15.4     14.8     14.3     13.7     −1.7     −2.2 to −1.2    \< 0.01   
   Adenocarcinoma                                                        Cases   1,731   1,838   2,205    2,177     2,404    2,561    2,859    3,041    3,232    3,780    4,024    4,414    4,900    5,045                              
  CR                                                                     7.3     7.7     9.2     9.0      9.9       10.5     11.7     12.4     13.1     15.3     16.2     17.7     19.5     20.0     8.3      7.8 to 8.8      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     8.8     9.0     10.4    9.8      10.3      10.5     11.3     11.5     11.7     13.1     13.3     14.0     14.9     14.7     4.1      3.6 to 4.6      \< 0.01   
   Small cell carcinoma                                                  Cases   1,260   1,238   1,355    1,408     1,460    1,530    1,474    1,557    1,721    1,733    1,839    1,969    1,971    2,045                              
  CR                                                                     5.3     5.2     5.6     5.8      6.0       6.3      6.0      6.4      7.0      7.0      7.4      7.9      7.9      8.1      3.5      3.1 to 4.0      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     6.4     6.1     6.4     6.5      6.4       6.4      5.9      6.0      6.3      6.1      6.1      6.2      6.0      5.9      −0.5     −0.9 to −0.1    0.01      
   Large cell carcinoma^[b)](#tfn2-crt-2016-178){ref-type="table-fn"}^   Cases   483     490     643      572       325      267      312      340      269      275      264      281      263      233                                
  CR                                                                     2.0     2.1     2.7     2.4      1.3       1.1      1.3      1.4      1.1      1.1      1.1      1.1      1.0      0.9      −6.8     −9.3 to −4.2    \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     2.5     2.4     3.1     2.6      1.4       1.1      1.3      1.3      1.0      1.0      0.9      0.9      0.8      0.7      −10.4    −12.8 to −7.9   \< 0.01   
   Other specified carcinomas                                            Cases   99      125     141      359       822      1,015    1,182    1,251    1,373    1,469    1,446    1,450    1,332    1,305                              
  CR                                                                     0.4     0.5     0.6     1.5      3.4       4.2      4.8      5.1      5.6      5.9      5.8      5.8      5.3      5.2      22.4     13.0 to 32.7    \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.5     0.6     0.7     1.6      3.6       4.2      4.7      4.8      5.0      5.1      4.8      4.6      4.1      3.8      17.9     8.7 to 28.0     \< 0.01   
   Sarcoma                                                               Cases   17      16      28       14        25       16       21       27       30       24       38       21       28       30                                 
  CR                                                                     0.1     0.1     0.1     0.1      0.1       0.1      0.1      0.1      0.1      0.1      0.2      0.1      0.1      0.1      4.0      0.5 to 7.7      0.03      
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.1     0.1     0.1     0.1      0.1       0.1      0.1      0.1      0.1      0.1      0.1      0.1      0.1      0.1      1.3      −2.3 to 5.0     0.46      
   Other specified cancer (including pulmonary blastoma)                 Cases   9       10      8        9         10       10       10       16       11       11       9        6        11       10                                 
  CR                                                                     0.0     0.0     0.0     0.0      0.0       0.0      0.0      0.1      0.0      0.0      0.0      0.0      0.0      0.0      −0.2     −3.4 to 3.0     0.88      
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.0     0.1     0.0     0.0      0.0       0.0      0.0      0.1      0.0      0.0      0.0      0.0      0.0      0.0      −3.9     −7.1 to −0.7    0.02      
   Unspecified cancer                                                    Cases   2,729   2,815   2,521    2,671     2,417    2,562    2,605    2,278    2,234    2,204    2,045    2,146    2,107    1,945                              
  CR                                                                     11.5    11.8    10.5    11.1     10.0      10.5     10.7     9.3      9.1      8.9      8.2      8.6      8.4      7.7      −3.0     −3.6 to −2.4    \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     15.7    15.6    13.5    13.7     12.0      12.0     11.8     9.8      9.2      8.6      7.5      7.4      6.9      6.0      −7.2     −7.8 to −6.5    \< 0.01   
  **Women**                                                                                                                                                                                                                             
   Overall                                                               Cases   3,458   3,588   3,654    3,913     3,987    4,379    4,728    5,035    5,234    5,523    5,791    6,223    6,657    6,738                              
  CR                                                                     14.7    15.2    15.3    16.3     16.6      18.1     19.5     20.7     21.4     22.4     23.4     25       26.6     26.8     5.2      4.8 to 5.5      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     12.9    12.9    12.7    13       12.8      13.5     14       14.5     14.4     14.5     14.6     15.2     15.6     15.3     1.7      1.4 to 2.0      \< 0.01   
   Carcinoma                                                             Cases   2,005   2,070   2,282    2,489     2,654    2,943    3,223    3,674    3,937    4,266    4,505    4,851    5,292    5,524                              
  CR                                                                     8.5     8.7     9.6     10.4     11.0      12.2     13.3     15.1     16.1     17.3     18.2     19.5     21.1     22.0     8.1      7.7 to 8.6      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     7.8     7.8     8.3     8.7      8.9       9.6      10.1     11.1     11.4     11.9     12.1     12.6     13.2     13.2     4.7      4.3 to 5.1      \< 0.01   
   Squamous cell carcinoma                                               Cases   364     357     367      386       375      427      427      503      443      439      440      485      523      473                                
  CR                                                                     1.5     1.5     1.5     1.6      1.6       1.8      1.8      2.1      1.8      1.8      1.8      1.9      2.1      1.9      2.2      1.3 to 3.1      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     1.4     1.3     1.3     1.3      1.2       1.3      1.3      1.4      1.2      1.1      1.1      1.1      1.2      1.0      −1.7     −2.6 to −0.8    \< 0.01   
   Adenocarcinoma                                                        Cases   1,195   1,267   1,394    1,479     1,626    1,834    2,029    2,314    2,601    2,864    3,178    3,422    3,839    4,161                              
  CR                                                                     5.1     5.4     5.8     6.2      6.8       7.6      8.4      9.5      10.6     11.6     12.8     13.7     15.3     16.5     10.0     9.6 to 10.5     \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     4.7     4.8     5.2     5.2      5.5       6.1      6.5      7.2      7.7      8.2      8.7      9.1      9.8      10.2     6.6      6.2 to 7.1      \< 0.01   
   Small cell carcinoma                                                  Cases   266     240     276      294       321      273      287      327      319      366      308      392      384      409                                
  CR                                                                     1.1     1.0     1.2     1.2      1.3       1.1      1.2      1.3      1.3      1.5      1.2      1.6      1.5      1.6      2.9      1.8 to 4.1      \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     1.0     0.9     1.0     1.0      1.0       0.8      0.9      0.9      0.9      0.9      0.8      0.9      0.9      0.9      −1.1     −2.1 to 0.0     0.06      
   Large cell carcinoma^[b)](#tfn2-crt-2016-178){ref-type="table-fn"}^   Cases   132     148     179      184       88       77       86       95       82       71       78       88       81       77                                 
  CR                                                                     0.6     0.6     0.8     0.8      0.4       0.3      0.4      0.4      0.3      0.3      0.3      0.4      0.3      0.3      −6.2     −9.2 to −3.1    \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.5     0.5     0.6     0.6      0.3       0.3      0.3      0.3      0.2      0.2      0.2      0.2      0.2      0.2      −9.9     −12.6 to −7.0   \< 0.01   
   Other specified carcinomas                                            Cases   48      58      66       146       244      332      394      435      492      526      501      464      465      404                                
  CR                                                                     0.2     0.2     0.3     0.6      1.0       1.4      1.6      1.8      2.0      2.1      2.0      1.9      1.9      1.6      19.1     11.3 to 27.5    \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.2     0.2     0.3     0.5      0.8       1.1      1.3      1.3      1.4      1.4      1.4      1.2      1.2      1.0      14.9     7.4 to 22.9     \< 0.01   
   Sarcoma                                                               Cases   9       4       7        8         12       12       18       16       15       7        5        24       16       10                                 
  CR                                                                     0.0     0.0     0.0     0.0      0.0       0.0      0.1      0.1      0.1      0.0      0.0      0.1      0.1      0.0      4.5      −2.6 to 12.1    0.20      
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.0     0.0     0.0     0.0      0.0       0.0      0.1      0.1      0.1      0.0      0.0      0.1      0.0      0.0      1.8      −4.8 to 8.8     0.58      
   Other specified cancer (include pulmonary blastoma)                   Cases   4       4       5        5         2        2        1        11       1        7        3        7        10       5                                  
  CR                                                                     0.0     0.0     0.0     0.0      0.0       0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      3.7      −7.2 to 15.9    0.48      
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     0.0     0.0     0.0     0.0      0.0       0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      1.4      −8.1 to 11.9    0.76      
   Unspecified cancer                                                    Cases   1,440   1,510   1,360    1,411     1,319    1,422    1,486    1,334    1,281    1,243    1,278    1,341    1,339    1,199                              
  CR                                                                     6.1     6.4     5.7     5.9      5.5       5.9      6.1      5.5      5.2      5.0      5.2      5.4      5.3      4.8      −1.6     −2.3 to −1.0    \< 0.01   
  ASR^[a)](#tfn1-crt-2016-178){ref-type="table-fn"}^                     5.1     5.1     4.3     4.3      3.8       3.8      3.8      3.3      2.9      2.6      2.5      2.5      2.4      2.0      −6.8     −7.5 to −6.1    \< 0.01   

CRs and ASRs were expressed per 100,000 people. CR, crude rate; ASR, age-standardized rate; APC, annual percent change; CI, confidence interval.

The Korean population in 2000 was used as standard population,

Large cell carcinoma includes giant cell, clear cell, and large cell undifferentiated carcinoma.

###### 

Joinpoint analysis for lung cancer mortality at all ages and at age 0-39, 40-59, 60-69, and ≥ 70, in the Republic of Korea, 1983-2013

              Trend 1     Trend 2               Trend 3     Trend 4                                                             
  ----------- ----------- --------------------- ----------- --------------------- ----------- --------------------- ----------- ---------------------
  **Men**                                                                                                                       
   All ages   1983-1994   9.4 (8.7 to 10.1)     1994-2002   1.6 (0.8 to 2.4)      2002-2013   −2.3 (−2.6 to −2.0)   \-          \-
   0-39       1983-1993   −1.4 (−3.6 to 0.9)    1993-2013   −5.4 (−6.4 to −4.5)   \-          \-                    \-          \-
   40-59      1983-1992   6.1 (5.2 to 7.0)      1992-2000   −2.3 (−3.2 to −1.3)   2000-2013   −4.7 (−5.0 to −4.3)   \-          \-
   60-69      1983-1987   13.7 (9.8 to 17.7)    1987-1994   9.4 (8.0 to 10.8)     1994-2001   −0.7 (−1.6 to 0.3)    2001-2013   −3.8 (−4.0 to −3.5)
   ≥ 70       1983-1994   14.2 (12.6 to 15.8)   1994-2002   6.3 (4.9 to 7.7)      2002-2013   −1.0 (−1.4 to −0.5)   \-          \-
  **Women**                                                                                                                     
   All ages   1983-1994   7.6 (6.6 to 8.6)      1994-2002   1.6 (0.4 to 2.7)      2002-2013   −1.4 (−1.9 to −0.9)   \-          \-
   0-39       1983-2013   −3.7 (−4.3 to −3.2)   \-          \-                    \-          \-                    \-          \-
   40-59      1983-1993   4.7 (3.3 to 6.1)      1993-2013   −1.5 (−1.9 to −1.2)   \-          \-                    \-          \-
   60-69      1983-1994   8.7 (7.5 to 9.9)      1994-2013   −1.6 (−1.9 to −1.2)   \-          \-                    \-          \-
   ≥ 70       1983-1994   13.6 (12.2 to 15.0)   1994-2002   5.4 (4.1 to 6.7)      2002-2013   −1.1 (−1.6 to −0.7)   \-          \-

Joinpoint regression models were used to detect significant changes in trends. APC, annual percent change; CI, confidence interval.

###### 

Five-year relative survival rates of lung cancer patient by sex and histological subtypes, the Korea Central Cancer Registry, 1993-2012

  Histological group             Year of diagnosis   Change^[a)](#tfn3-crt-2016-178){ref-type="table-fn"}^ (%)   p-value^[b)](#tfn4-crt-2016-178){ref-type="table-fn"}^                                                                                                  
  ------------------------------ ------------------- ----------------------------------------------------------- -------------------------------------------------------- ---------- ------------ ---------- ------------ ---------- ------------- ---------- ---------- -------------
  **Overall total**              **37,145**          **12.0**                                                    **59,279**                                               **14.3**   **73,116**   **17.4**   **88,559**   **21.9**   **258,099**   **17.4**   **9.9**    **\< 0.01**
   Carcinoma                     29,798              11.5                                                        45,528                                                   14.2       59,851       18.4       76,061       23.9       211,238       18.3       12.4       \< 0.01
    Squamous cell carcinoma      13,431              13.6                                                        18,209                                                   16.4       20,631       19.5       22,165       22.2       74,436        18.4       8.6        \< 0.01
    Adenocarcinoma               8,841               10.4                                                        15,490                                                   14.6       22,148       23.1       34,187       32.1       80,666        23.4       21.7       \< 0.01
    Small-cell carcinoma         5,179               6.2                                                         7,467                                                    8.0        8,739        7.5        10,432       8.0        31,817        7.6        1.8        \< 0.01
    Large-cell carcinoma         1,834               9.7                                                         3,229                                                    9.3        1,824        10.6       1,555        12.6       8,442         10.2       2.9        0.42
    Other specified carcinomas   513                 33.2                                                        1,133                                                    30.4       6,509        15.2       7,722        17.0       15,877        17.8       --16.2     \< 0.01
   Sarcoma                       71                  18.0                                                        118                                                      20.5       153          12.5       150          23.1       492           17.6       5.1        0.88
   Other specified cancer        55                  28.0                                                        54                                                       32.1       59           47.2       66           22.7       234           33.3       --5.3      0.35
   Unspecified cancer            7,221               14.0                                                        13,579                                                   14.3       13,053       13.1       12,282       8.9        46,135        12.7       --5.1      \< 0.01
  **Men**                                                                                                                                                                                                                                                                
   Total                         **28,695**          **11.2**                                                    **44,342**                                               **12.9**   **53,690**   **15.9**   **62,863**   **19.3**   **189,590**   **15.5**   **8.1**    **\< 0.01**
   Carcinoma                     23,575              11.1                                                        35,235                                                   13.5       45,080       17.0       54,900       21.0       158,790       16.6       9.9        \< 0.01
    Squamous cell carcinoma      12,099              13.7                                                        16,493                                                   16.5       18,705       20.0       20,099       22.7       67,396        18.7       9.0        \< 0.01
    Adenocarcinoma               5,366               9.0                                                         9,263                                                    12.4       12,747       19.9       19,087       27.1       46,463        19.8       18.1       \< 0.01
    Small-cell carcinoma         4,299               5.6                                                         6,197                                                    7.5        7,298        7.4        8,694        8.2        26,488        7.4        2.6        \< 0.01
    Large-cell carcinoma         1,450               9.4                                                         2,500                                                    8.9        1,424        10.5       1,198        13.4       6,572         10.1       4.0        0.17
    Other specified carcinomas   361                 28.6                                                        782                                                      25.0       4,906        14.0       5,822        15.9       11,871        16.1       --12.7     \< 0.01
   Sarcoma                       45                  16.8                                                        82                                                       15.6       95           7.0        110          21.5       332           14.3       4.7        0.89
   Other specified cancer        44                  28.2                                                        36                                                       25.2       44           37.4       42           18.2       166           28.1       --10.0     0.20
   Unspecified cancer            5,031               11.2                                                        8,989                                                    10.3       8,471        10.0       7,811        7.2        30,302        9.7        --4.0      \< 0.01
  **Women**                                                                                                                                                                                                                                                              
   Total                         **8,450**           **14.7**                                                    **14,937**                                               **18.3**   **19,426**   **21.7**   **25,696**   **28.2**   **68,509**    **22.4**   **13.5**   **\< 0.01**
   Carcinoma                     6,223               12.7                                                        10,293                                                   16.8       14,771       22.6       21,161       31.5       52,448        23.4       18.8       \< 0.01
    Squamous cell carcinoma      1,332               12.3                                                        1,716                                                    15.2       1,926        15.1       2,066        17.3       7,040         15.2       5.0        0.02
    Adenocarcinoma               3,475               12.6                                                        6,227                                                    17.8       9,401        27.5       15,100       38.3       34,203        28.2       25.7       \< 0.01
    Small-cell carcinoma         880                 9.1                                                         1,270                                                    10.5       1,441        8.3        1,738        7.1        5,329         8.7        --2.0      \< 0.01
    Large-cell carcinoma         384                 10.8                                                        729                                                      10.8       400          10.7       357          9.5        1,870         10.7       --1.3      0.39
    Other specified carcinomas   152                 44.1                                                        351                                                      42.1       1,603        18.8       1,900        20.5       4,006         23.0       --23.6     \< 0.01
   Sarcoma                       26                  20.1                                                        36                                                       31.6       58           21.2       40           27.0       160           24.3       6.9        0.95
   Other specified cancer        11                  27.5                                                        18                                                       45.3       15           76.0       24           31.4       68            46.2       3.9        0.99
   Unspecified cancer            2,190               20.5                                                        4,590                                                    22.0       4,582        18.9       4,471        11.8       15,833        18.5       --8.7      \< 0.01

Change (%) in the 5-year relative survival rates from 1993-1997 to 2008-2012,

p-values for changes in survival from 1993-1997 and 2008-2012 were derived by relative excess risk model.

[^1]: Present address: AS worked at the National Cancer Center until August 2013, and is now with the Seoul National University College of Medicine.
